LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program
May 15th 2008Drug InformationCholesterol
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company’s Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect. “The Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
